The overall goal of this funding opportunity announcement (FOA) is to improve the treatment of adult glioblastoma (GBM) by developing novel effective agents that can cross the blood brain barrier (BBB) and testing them in the clinic. To implement this initiative, multi-institutional teams are invited to participate in the Glioblastoma Therapeutics Network (GTN). Each GTN team is expected to drive therapeutic agent(s) from pre-clinical development, through IND studies, into pilot clinical studies in humans.
Application or LOI Due Date
LOI due 10/19/20 for application due date of 11/19/20